Hyperprolactinemia inhibits natural killer (NK) cell functionin vivo and its bromocriptine treatment not only corrects it but makes it more efficient
- 1 May 1992
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 12 (3) , 210-215
- https://doi.org/10.1007/bf00918091
Abstract
We studied NK cell function in eight patients with pathological hyperprolactinemia by measuring51Cr release by K562 cells exposed to their mononuclear cells and found it decreased compared to normal controls (PP=0.01). The study of NK cell function in agarose revealed that its decrease in hyperprolactinemia is due to their low active binding to target cells, active killing, and recycling capacity. BrC tended to correct them but also increased recycling capacity to levels higher than those of controls (P<0.05). Sequential studies in three hyperprolactinemic patients before and after BrC showed correction of NK function within 1 week but its increased efficiency at the 12:1 effector:target ratio required 8 weeks. We conclude that hyperprolactinemia decreases NK cell function. BrC corrects this by decreasing prolactin levels but also makes NK function more efficient by increasing the capacity of NK cells to recycle after killing.Keywords
This publication has 21 references indexed in Scilit:
- Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitisClinical Immunology and Immunopathology, 1990
- Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantationThe Annals of Thoracic Surgery, 1990
- Natural killer activity in hyperprolactinemic patientsImmunopharmacology, 1989
- Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemiaJournal of Clinical Immunology, 1987
- Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat.Journal of Clinical Investigation, 1987
- Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine.Proceedings of the National Academy of Sciences, 1986
- T-cell dysregulation in patients with hyperprolactinemia: Effect of bromocriptine treatmentClinical Immunology and Immunopathology, 1986
- Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2Journal of Clinical Immunology, 1984
- Immunomodulation by bromocriptineImmunopharmacology, 1983
- Recycling and target binding capacity of human natural killer cells.The Journal of Experimental Medicine, 1981